login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
EDITAS MEDICINE INC (EDIT) Stock News
USA
- NASDAQ:EDIT -
US28106W1036
-
Common Stock
3.72
USD
+0.07 (+1.92%)
Last: 10/24/2025, 8:20:34 PM
3.7584
USD
+0.04 (+1.03%)
After Hours:
10/24/2025, 8:20:34 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
EDIT Latest News, Press Relases and Analysis
All
Press Releases
19 days ago - By: Chartmill
Editas Medicine Inc (NASDAQ:EDIT) Shows High Growth Momentum and Strong Technical Trend
17 days ago - By: Editas Medicine, Inc.
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
17 days ago - By: Editas Medicine, Inc.
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
20 days ago - By: Editas Medicine, Inc.
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
20 days ago - By: Editas Medicine, Inc.
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
a month ago - By: Benzinga
- Mentions:
ILMN
VRTX
LLY
NVO
...
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years
2 months ago - By: Benzinga
Editas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
2 months ago - By: Zacks Investment Research
- Mentions:
CRMD
KNSA
PHAR
Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol
2 months ago - By: Editas Medicine, Inc.
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
2 months ago - By: Editas Medicine, Inc.
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
2 months ago - By: Editas Medicine, Inc.
Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
2 months ago - By: Editas Medicine, Inc.
Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
2 months ago - By: Editas Medicine, Inc.
Editas Medicine to Participate in Upcoming Investor Conferences
2 months ago - By: Editas Medicine, Inc.
Editas Medicine to Participate in Upcoming Investor Conferences
3 months ago - By: Zacks Investment Research
- Mentions:
DARE
Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates
3 months ago - By: Editas Medicine, Inc.
Editas Medicine Announces Second Quarter 2025 Results and Business Updates
3 months ago - By: Editas Medicine, Inc.
Editas Medicine Announces Second Quarter 2025 Results and Business Updates
3 months ago - By: Zacks Investment Research
- Mentions:
TCRX
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates
3 months ago - By: Zacks Investment Research
- Mentions:
HUMA
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates
4 months ago - By: The Motley Fool
- Mentions:
SRPT
2 Beaten-Down Stocks to Avoid
4 months ago - By: Yahoo Finance
- Mentions:
WWD
NTLA
BAC
Editas Medicine Is Great. Here's Why You Shouldn't Buy It.
4 months ago - By: The Motley Fool
Editas Medicine Is Great. Here's Why You Shouldn't Buy It.
4 months ago - By: Investor's Business Daily
- Mentions:
LLY
VERV
NTLA
CRSP
...
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
5 months ago - By: Editas Medicine, Inc.
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
5 months ago - By: Editas Medicine, Inc.
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
5 months ago - By: Yahoo Finance
- Mentions:
BAC
O
EPD
LMT
...
1 Stock Down 97% That Could Double, According to Wall Street
5 months ago - By: Yahoo Finance
- Mentions:
TSM
O
AAPL
AMZN
...
4 Reasons to Buy Taiwan Semiconductor Manufacturing Stock Like There's No Tomorrow
Please enable JavaScript to continue using this application.